⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533682 | 0.78 | — | — | |
| SCHEMBL4700565 | 0.77 | CNR2 (0.31) | — | |
| SCHEMBL17374883 | 0.77 | ECE1 (0.40) | — | |
| SCHEMBL103565 | 0.76 | — | — | |
| SCHEMBL1198255 | 0.76 | — | — | |
| SCHEMBL102234 | 0.76 | — | — | |
| SCHEMBL5233601 | 0.76 | — | — | |
| SCHEMBL2724855 | 0.76 | — | — | |
| SCHEMBL12359888 | 0.76 | — | — | |
| Iodide SCHEMBL31511841 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20170216290-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-9683003-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170002032-A9 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160009744-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2015154169-A1 | BINDING FUNCTION3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-10-15 | — | — | WO | disclosed |
| US-7579366-B2 | Epothilone derivatives and their synthesis and use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579366-B2 | Epothilone derivatives and their synthesis and use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-08-25 | — | — | US | disclosed |
| US-7173137-B2 | Epothilone analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-06 | — | — | US | disclosed |
| US-20030203938-A1 | Epothilone derivatives and their synthesis and use | THE SCRIPPS RESEARCH INSTITUTE | 2003-10-30 | — | — | US | disclosed |
| US-6531497-B1 | Proliferative diseases | THE SCRIPPS RESEARCH INSTITUTE | 2003-03-11 | — | — | US | disclosed |
| US-6441186-B1 | ANTICANCER AGENTS; PREVENTION OF MITOSIS THROUGH INDUCTION AND STABILIZATION OF MICROTUBULIN ASSEMBLY; SUPERIOR CYTOTOXIC ACTIVITIES | THE SCRIPPS RESEARCH INSTITUTE | 2002-08-27 | — | — | US | disclosed |
| US-6380394-B1 | ANTICANCER AGENTS | THE SCRIPPS RESEARCH INSTITUTE | 2002-04-30 | — | — | US | disclosed |
| CN-1306531-A | Epsilon derivatives and their synthesis and use | NOVARTIS AG (CH) | 2001-08-01 | — | — | CN | disclosed |
| EP-1089998-A2 | EPOTHILONE DERIVATIVES AND THEIR SYNTHESIS AND USE | Novartis AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| CN-1246862-A | Epothilone analogs | NOVARTIS AG (CH) | 2000-03-08 | — | — | CN | disclosed |
| WO-1999067252-A2 | EPOTHILONE DERIVATIVES AND THEIR SYNTHESIS AND USE | NOVARTIS AG (CH) | 1999-12-29 | — | — | WO | disclosed |
| EP-0944634-A1 | EPOTHILONE ANALOGS | Novartis AG (CH) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025929-A1 | EPOTHILONE ANALOGS | NOVARTIS AG (CH) | 1998-06-18 | — | — | WO | disclosed |